Investment in Consumer Health Technology Reaches New Heights in 2024
Global, Friday, 4 April 2025.
In 2024, global investment in consumer health technology surged by 9%, totaling $4.5 billion, with notable growth in women’s health technologies, highlighted by Flo Health’s $200 million funding.
Regional Growth and Market Leadership
North America continues to dominate the consumer health technology landscape, capturing 64% of total funding and 78% of global venture capital deals in 2024 [1]. This market leadership is particularly significant as European digital health funding showed remarkable growth, with a 27% year-over-year increase, outpacing the global growth rate of 5.5% [5]. The surge in investment has been notably driven by AI-powered healthcare solutions, which accounted for 58% of European funding [5].
Women’s Health Technology Breakthrough
Women’s health technology has emerged as a major investment focus, reaching an unprecedented $2.6 billion in 2024, marking a significant increase of nearly $1 billion from 2023 [6]. This sector’s expansion is particularly noteworthy as it represents a broader trend, with total investment in women’s health-related diseases reaching $10.7 billion [6]. The transformation is evident in the investment structure, with seed and Series A deals representing 70% of total deals in 2024, down from 83% in 2023, indicating increasing maturity in the sector [6].
Market Segmentation and Innovation
Mental health solutions led the funding distribution in 2024, securing $1.31 billion or 29% of total investment, showing a 33% increase from the previous year [3]. Women’s health captured the second position with $866 million, while preventive health secured $779 million [3]. The sector witnessed significant megadeals, with 11 transactions totaling $1.6 billion, accounting for 37% of all funding [3]. Notable deals included Neko Health’s $260 million Series B and eGym’s $201 million Series H financing [1].
Future Outlook and Industry Partnerships
The consumer health technology sector is experiencing increased integration with traditional healthcare systems, as evidenced by over 900 new partnerships formed in 2024 [1]. Major corporate players have shown sustained interest, with Walmart leading with 19 partnerships, followed by Pfizer (13), Mayo Clinic (12), Aetna (11), and Amazon (11) [3]. However, the industry faces challenges in clinical validation, with only 20% of mental health ventures and 21% of preventive health ventures demonstrating strong clinical evidence [3]. As the sector matures, there is an increasing focus on addressing these validation gaps while maintaining the momentum of technological innovation [1].